Lucid Diagnostics (NASDAQ:LUCD) Given New $2.60 Price Target at Needham & Company LLC

Lucid Diagnostics (NASDAQ:LUCD – Get Rating) had its price target trimmed by Needham & Company LLC from $3.10 to $2.60 in a report released on Tuesday morning, Benzinga reports. The firm currently has a buy rating on the stock.

Separately, BTIG Research reduced their target price on shares of Lucid Diagnostics from $5.00 to $3.50 and set a buy rating on the stock in a research note on Friday, November 18th.

Lucid Diagnostics Price Performance

Shares of LUCD stock opened at $1.72 on Tuesday. The stock’s fifty day simple moving average is $1.37 and its 200 day simple moving average is $1.66. Lucid Diagnostics has a one year low of $1.11 and a one year high of $3.64. The firm has a market cap of $67.27 million, a price-to-earnings ratio of -1.19 and a beta of 1.99.

Institutional Investors Weigh In On Lucid Diagnostics

A number of large investors have recently bought and sold shares of the business. Luminus Management LLC raised its position in Lucid Diagnostics by 15.7% in the 2nd quarter. Luminus Management LLC now owns 873,804 shares of the company’s stock valued at $1,975,000 after purchasing an additional 118,322 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Lucid Diagnostics by 25.6% in the first quarter. Vanguard Group Inc. now owns 312,876 shares of the company’s stock valued at $1,051,000 after buying an additional 63,687 shares in the last quarter. Geneos Wealth Management Inc. bought a new position in shares of Lucid Diagnostics in the first quarter valued at about $209,000. Levin Capital Strategies L.P. acquired a new position in Lucid Diagnostics during the 4th quarter worth about $50,000. Finally, Verition Fund Management LLC bought a new stake in Lucid Diagnostics during the 1st quarter worth about $122,000. 5.89% of the stock is currently owned by institutional investors.

Lucid Diagnostics Company Profile

(Get Rating)

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.